Linagliptine Abdi

Linagliptin, the active ingredient in Linagliptine Abdi, is a DPP-4 inhibitor presented as an unknown/unknown for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptine Abdi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus. - Monotherapy in type 2 diabetes: provides glycaemic control as a single oral agent. - Combination with metformin: enhances overall glucose‑lowering effect when diet and exercise are insufficient. - Combination with insulin: helps reduce insulin dose requirements and stabilises blood glucose levels.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: symptoms of cough and congestion. - Dizziness: occasional light‑headed sensation. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Hypersensitivity reactions: angioedema or Stevens‑Johnson syndrome.

Linagliptine should be used with clinical oversight and consideration of patient‑specific factors. - Renal impairment: assess renal function before initiating therapy. - Hepatic impairment: monitor liver enzymes regularly. - History of pancreatitis: avoid use or discontinue if symptoms recur. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptine may interact with other medicines and requires monitoring. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin exposure. - Concomitant insulin therapy: increased risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Sulfonylureas: may potentiate hypoglycaemic episodes. - Diuretics and ACE inhibitors: monitor renal function and electrolytes. - Warfarin: watch INR values for potential anticoagulant effect changes.